1. Home
  2. FRPH vs TRDA Comparison

FRPH vs TRDA Comparison

Compare FRPH & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

HOLD

Current Price

$22.57

Market Cap

435.3M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.69

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPH
TRDA
Founded
1986
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.3M
481.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FRPH
TRDA
Price
$22.57
$12.69
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
38.9K
196.5K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$41,774,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$53.29
P/E Ratio
$140.75
N/A
Revenue Growth
0.65
N/A
52 Week Low
$21.68
$4.93
52 Week High
$29.68
$13.99

Technical Indicators

Market Signals
Indicator
FRPH
TRDA
Relative Strength Index (RSI) 31.13 55.05
Support Level $21.93 $9.78
Resistance Level $24.59 N/A
Average True Range (ATR) 0.49 0.92
MACD -0.19 0.09
Stochastic Oscillator 11.16 53.40

Price Performance

Historical Comparison
FRPH
TRDA

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: